Reference : Projet TADAM: RAPPORT FINAL 2007-2013
Reports : External report
Law, criminology & political science : Criminology
Human health sciences : Psychiatry
Human health sciences : Public health, health care sciences & services
Projet TADAM: RAPPORT FINAL 2007-2013
[en] TADAM trial: final report 2007-2013
Demaret, Isabelle mailto [Université de Liège - ULiège > Département des sciences cliniques > Psychiatrie et psychologie médicale >]
Litran, Géraldine []
Magoga, Cécile []
Deblire, Clémence []
Van Caillie, Didier [Université de Liège - ULiège > HEC-Ecole de gestion : UER > Diagnostic et contrôle de l'entreprise >]
Lemaître, André [Université de Liège - ULiège > Institut des sciences humaines et sociales > Criminologie >]
ANSSEAU, Marc [Centre Hospitalier Universitaire de Liège - CHU > > Psychiatrie et psychologie médicale >]
Quertemont, Etienne [Université de Liège - ULiège > Département de Psychologie : cognition et comportement > Psychologie quantitative >]
DUBOIS, Nathalie [Centre Hospitalier Universitaire de Liège - CHU > > Toxicologie clinique >]
CHARLIER, Corinne [Centre Hospitalier Universitaire de Liège - CHU > > Toxicologie clinique >]
De Roubaix, Jérôme []
Université de Liège
[fr] Assuétude ; Heroïne ; Traitement ; Etude contrôlée randomisée
[en] Background: Heroin-assisted treatment (HAT) can improve the condition of heroin addicts resistant to other treatment. A new trial compared HAT and methadone treatment with HAT limited to 12 months in order to assess its feasibility and efficacy in Belgium.
Methods: TADAM (Treatment Assisted by Diacetylmorphine) was an open label randomised controlled trial. The experimental treatment was based upon the Swiss model of HAT developed in 1994. The primary efficacy criterion was determined by an improvement in street heroin use or in (physical or mental) health or a decrease in criminal involvement. Participants were assessed every 3 months. Self-reported data were complemented with toxicological analyses and criminal proceedings.
Findings: 74 participants were randomised in the trial: 36 in the experimental group and 38 in the control group. The experimental group counted 30% of responders more than the control group at 3 months (p<0.05), 6 months (p<0.05), and 9 months (p<0.01). At 12 months, the number of responders was still higher in the experimental group (11%) but the difference was no longer significant (p=0.35). Street heroin use increased in the experimental group at the 12-month assessment just before the end of HAT.
Conclusion: HAT is feasible and effective. However, HAT should not have a predetermined duration for heroin users for which heroin addiction became a chronic relapsing disease.
Other data: In addition to the outcomes of the randomised controlled trial, the report contains other exploratory data and analysis: satisfaction of in treatment, criminological data, opinion of heroin users not included in the trial, opinion of caregivers and field workers (in the HAT centre, in the partner centres, and in other centres in the addiction field), impact of the HAT centre on its neighbourhood and a socio-economic evaluation.
Funding: The TADAM trial was funded at 80% by the Federal Minister of Social Affairs and Public Health. It was also funded the City and the University of Liège.
[nl] Een vertaling in het Nederlands van het document met de samenvattingen is hieronder beschikbaar.
Université de Liège
Ministre fédérale de la Santé publique ; Université de Liège ; Ville de Liège
Projet TADAM, un projet pilote de traitement assisté par diacétylmorphine
Researchers ; Professionals ; Students ; General public
Les articles publiés sur le projet (constituant la section I de ce rapport) sont référencés séparément sur Orbi :
Demaret, I., Lemaitre, A., & Ansseau, M. (2013). [Heroin]. Rev Med Liege, 68(5-6), 287-293.
Demaret, I., Herné, P., Lemaître, A., & Ansseau, M. (2011). Feasibility assessment of heroin-assisted treatment in Liège, Belgium. Acta Psychiatrica Belgica, 111(1), 3-8.
Demaret, I., Lemaitre, A., & Ansseau, M. (2010). [Efficacy of the treatment assisted by diacetylmorphine (pharmaceutical heroin)]. Rev Med Liege, 65(12), 681-687.
Demaret, I., Lemaitre, A., & Ansseau, M. (2012). Staff concerns in heroin-assisted treatment centres. J Psychiatr Ment Health Nurs, 19(6), 563-567. doi: 10.1111/j.1365-2850.2011.01810.x

File(s) associated to this reference

Fulltext file(s):

Open access
TADAM.RptFin&Syntheses.pdfRapport final avec une synthèse de chaque chapitre (48 pp.)Author postprint299.21 kBView/Open
Open access
TADAM.RptFin.II.Protocole&Annexes.pdfSection II. Le protocole avec ses 4 premières annexesAuthor postprint1.73 MBView/Open
Open access
TADAM.RptFin.III.A.DeroulInclusion.pdfSection III. Chapitre A. Déroulement de l'inclusionAuthor postprint617.57 kBView/Open
Open access
TADAM.RptFin.III.B.Motivations.pdfSection III. Chapitre B. Motivations à participer au projetAuthor postprint241.37 kBView/Open
Open access
TADAM.RptFin.III.C.CentresReferents.pdfSection III. Chapitre C. Les centres référentsAuthor postprint384.18 kBView/Open
Open access
TADAM.RptFin.III.D.CaractPatients.pdfSection III. Chapitre D. Caractéristiques des patients et annexesAuthor postprint769.55 kBView/Open
Open access
TADAM.RptFin.III.E.Efficacite.pdfSection III. Chapitre E. Efficacité - Résultats de l'étude contrôlée randomiséeAuthor postprint967.17 kBView/Open
Open access
TADAM.RptFin.III.F.EvalSocioEcono.pdfSection III. Chapitre F. Evaluation socioéconomiqueAuthor postprint845.55 kBView/Open
Open access
TADAM.RptFin.III.G.AspectsCrimino.pdfSection III. Chapitre G. Aspects criminologiquesAuthor postprint291.9 kBView/Open
Open access
TADAM.RptFin.III.H.SatisfPatients.pdfSection III. Chapitre H. Satisfaction des patients en traitementAuthor postprint371.09 kBView/Open
Open access
TADAM.RptFin.III.I.ObservCentreDAM.pdfSection III. Chapitre I. Observations dans le centre DAMAuthor postprint3.51 MBView/Open
Open access
TADAM.RptFin.III.K.ExperSoignants.pdfSection III. Chapitre K. Expérience des soignants du centre DAMAuthor postprint234.75 kBView/Open
Open access
TADAM.RptFin.III.L.INTRES.pdfSection III. Chapitre L. INTRES: Intégration du centre DAM dans le réseau et le circuit de soinsAuthor postprint665.27 kBView/Open
Open access
TADAM.RptFin.III.M.IMPEN&Annexes.pdfSection III. Chapitre M. IMPEN - Impact du centre DAM sur son environnement urbainAuthor postprint32.79 MBView/Open
Open access
TADAM.RptFin.IV.Recommandations.pdfSection IV. RecommandationsAuthor postprint196.19 kBView/Open
Open access
TADAM RptFin&Samenvattingen_NL.pdfVertaling (door de FOD Volksgezondheid) in het Nederlands van de samenvattingenAuthor postprint315.91 kBView/Open
Open access
TADAM.CommuniquéPresse.pdfCommuniqué de presse annonçant les résultats de l'étude TADAMAuthor postprint831 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.